Cover Image
市場調查報告書

移植的組織適合性檢驗的全球市場 2021年:血清檢驗、MLC檢驗、PCR (聚合酵素鏈鎖反應) 、NGS (次世代定序)

HLA Typing For Transplant Market By Technology (Sso-Pcr, Ssp-Pcr, Ngs, Sanger's Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) Forecast To 2021

出版商 MarketsandMarkets 商品編碼 327987
出版日期 內容資訊 英文 185 Pages
訂單完成後即時交付
價格
Back to Top
移植的組織適合性檢驗的全球市場 2021年:血清檢驗、MLC檢驗、PCR (聚合酵素鏈鎖反應) 、NGS (次世代定序) HLA Typing For Transplant Market By Technology (Sso-Pcr, Ssp-Pcr, Ngs, Sanger's Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) Forecast To 2021
出版日期: 2016年05月06日 內容資訊: 英文 185 Pages
簡介

移植的組織適合性檢驗 (器官移植實驗) 的市場預計從2016年到2021年以7.1%的年複合成長率成長,到2021年達到7億5,390萬美元的規模。該市場成長,是起因於固態內臟器官、軟組織、幹細胞移植數的增加,技術進步,及資金、研究獎金、官民投資的增加等要素。可是,NGS、PCR為基礎的產品相關設備的高成本性及對於內臟器官提供、器官移植手術醫療費償付的限制,抑制器官移植檢驗市場成長。加上,從血清檢驗轉換到遺傳基因為基礎的HLA分析,及新興各國的醫療基礎設施的改善,提供器官移植檢驗市場各種機會。

本報告提供移植的組織適合性檢驗的全球市場調查,市場概要與產業結構,各技術區分、產品&服務區分、終端用戶、用途的市場趨勢及市場成長預測,各地區及各主要國家趨勢,市場成長的主要影響因素及市場機會分析,競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 全球移植的組織適合性檢驗 (器官移植檢驗) 市場概要
  • 全球器官移植檢驗技術市場:各地區
  • 全球器官移植檢驗產品與服務市場
  • 全球器官移植檢驗用途市場:各地區
  • 全球器官移植檢驗市場:各終端用戶
  • 全球器官移植檢驗市場:各國

第5章 市場概要

  • 簡介
  • 市場區隔
  • 市場動態
    • 主要的成長推進因素
    • 主要的阻礙成長要素
    • 主要市場機會
    • 主要市場課題

第6章 產業趨勢

  • 簡介
  • 價值鏈分析
  • 產業趨勢
    • 先進技術和分子檢驗手法的整合
  • 波特的五力分析

第7章 移植的組織適合性檢驗的市場:各技術

  • 簡介
  • 分子檢驗
    • PCR為基礎的
      • PCR-SSP (Sequence Specific Primer)
      • PCR-SSO (Sequence Specific Oligonucleotide)
    • 定序為基礎的
      • Sanger定序法
      • 次世代定序法
  • 非分子檢驗
    • 血清檢驗
    • MLC檢驗 (淋巴球混合培養檢驗)

第8章 移植的組織適合性檢驗的市場:各產品與服務

  • 簡介
  • 試劑、消耗品
  • 設備
  • 軟體、服務

第9章 移植的組織適合性檢驗的市場:各用途

  • 簡介
  • 診斷
  • 研究

第10章 移植的組織適合性檢驗的市場:各終端用戶

  • 簡介
  • 醫院、移植中心
  • 商用服務供應商
  • 研究實驗室、學術機構

第11章 移植的組織適合性檢驗的市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他的歐洲 (ROE)
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他的亞太地區 (ROAPAC)
  • 其他 (ROW)

第12章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭模式
  • 近幾年的發展趨勢
    • 協定、聯盟
    • 新產品的投入、產品的改良
    • 策略基準
    • 地區的擴張

第13章 企業簡介

  • 簡介
    • 地區基準
    • 策略基準
  • THERMO FISHER SCIENTIFIC, INC.
  • IMMUCOR, INC.
  • OLERUP SSP AB
  • QIAGEN N.V.
  • BIO-RAD LABORATORIES, INC.
  • ILLUMINA, INC.
  • AFFYMETRIX, INC.
  • F. HOFFMANN-LA-ROCHE LIMITED
  • LUMINEX CORPORATION
  • ABBOTT LABORATORIES, INC.
    • 產業概要
    • 產品與服務
    • 近幾年的發展趨勢
    • MNM的見解

第14章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 3686

The global transplant diagnostics market is projected to reach USD 753.9 million by 2021 from USD 535.0 million in 2016, growing at a CAGR of 7.1%, during 2016 to 2021. Market growth can be attributed to factors such as rising number of solid organ, soft tissue, and stem cell transplantations; technological advancements; and increased funding, research grants, and public-private investments. However, high device costs associated with NGS and PCR-based devices and limited medical reimbursements for organ donation and transplantation procedures restrain the growth of the transplant diagnostics market. Furthermore, the technological shift from serological assays to gene-based HLA profiling and improving healthcare infrastructure across developing countries provide various opportunities in the transplant diagnostics market. The significant gap between the number of organs donated and the number of organs required annually is however a major challenge limiting the growth of the global transplant diagnostics market to a certain extent.

In this report, the global transplant diagnostics market is segmented on the basis of technology into molecular assay technology [including PCR-based (sequence-specific oligonucleotide and sequence-specific primer-PCR) and sequencing-based (next-generation sequencing and Sanger sequencing)] and non-molecular assay technology (includes serological and mixed lymphocyte culture assay); products and services (reagents and consumables, instruments, and software & services); applications (diagnostic and research); and end users (hospitals & transplant centers, commercial service providers, and research laboratories & academic institutes).

Geographically, North America and Europe are expected to be the mature markets for transplant diagnostics products in 2016. The North American transplant diagnostics market is expected to hold the largest share of global transplant diagnostics market in 2016; it is projected to grow at the highest CAGR during the forecast period owing to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS), increasing prevalence of target diseases (such as cancer, heart failure, and renal diseases) in the U.S. and Canada, and continuous technological advancements in the field of transplant diagnostics.

As of 2015, the key players in the transplant diagnostics market included Thermo Fischer Scientific, Inc. (U.S.), Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis such as market share analysis of the top ten players and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the transplant diagnostics market, and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms to garner a higher market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the transplant diagnostic products offered by the top 10 players in the global market. The report analyzes the transplant diagnostics market by technology, products and services, end user, and application across key geographic regions
  • Product Development/Innovation: Detailed insights on the upcoming transplant diagnostics products, research and development activities, and new product launches in the market
  • Market Development: Comprehensive information on the lucrative emerging markets. The report analyzes the markets for various transplant diagnostic products across key geographic regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global transplant diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the global transplant diagnostics market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. GEOGRAPHIC SCOPE
    • 1.3.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Breakdown of Primaries
  • 2.2. OPPORTUNITY INDICATORS
    • 2.2.1. INTRODUCTION
    • 2.2.2. DEMAND-SIDE ANALYSIS
      • 2.2.2.1. Healthcare expenditure patterns
      • 2.2.2.2. Rapid growth in geriatric population
      • 2.2.2.3. Rising incidence and prevalence of cancer
      • 2.2.2.4. Growing burden of cardiovascular diseases (CVDs)
      • 2.2.2.5. Increasing number of organ donations and transplantations
    • 2.2.3. SUPPLY-SIDE ANALYSIS
      • 2.2.3.1. Number of new product launches: HLA-based transplant diagnostics Vs. competitive technologies
      • 2.2.3.2. Parent market analysis: Immunoassay market
  • 2.3. MARKET SIZE ESTIMATION
    • 2.3.1. BOTTOM-UP APPROACH
    • 2.3.2. TOP-DOWN APPROACH
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. RESEARCH ASSUMPTIONS
    • 2.5.1. ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL HLA TYPING FOR TRANSPLANT MARKET OVERVIEW
  • 4.2. GLOBAL HLA-BASED TRANSPLANT DIAGNOSTIC TECHNOLOGY MARKET, BY REGION (2016)
  • 4.3. GLOBAL HLA-BASED TRANSPLANT DIAGNOSTICS PRODUCT AND SERVICES MARKET, BY REGION (2016-2021)
  • 4.4. GLOBAL HLA TYPING FOR TRANSPLANT APPLICATIONS MARKET, BY REGION (2016-2021)
  • 4.5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, BY END USER (2016-2021)
  • 4.6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY (2016-2021)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. KEY MARKET DRIVERS
      • 5.3.1.1. Growing number of solid organ, soft-tissue, and stem cell transplantation procedures
      • 5.3.1.2. Technological advancements in the field of HLA typing
      • 5.3.1.3. Increased funding, research grants, and public-private investments
    • 5.3.2. KEY MARKET RESTRAINTS
      • 5.3.2.1. High cost of NGS and PCR-based devices
      • 5.3.2.2. Limited medical reimbursements for organ donation and transplantation procedures
    • 5.3.3. KEY MARKET OPPORTUNITIES
      • 5.3.3.1. Technological shift from serological assays to gene-based HLA profiling
      • 5.3.3.2. Improving healthcare infrastructure across developing countries
    • 5.3.4. KEY MARKET CHALLENGES
      • 5.3.4.1. Significant gap between number of organs donated and organs required annually

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. INDUSTRY TRENDS
    • 6.3.1. INTEGRATION OF ADVANCED TECHNOLOGIES WITH MOLECULAR ASSAY PROCEDURE
  • 6.4. PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1. THREAT OF NEW ENTRANTS
    • 6.4.2. THREAT OF SUBSTITUTES
    • 6.4.3. BARGAINING POWER OF SUPPLIERS
    • 6.4.4. BARGAINING POWER OF BUYERS
    • 6.4.5. INTENSITY OF COMPETITIVE RIVALRY

7. HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. MOLECULAR ASSAYS
    • 7.2.1. PCR-BASED MOLECULAR ASSAYS
      • 7.2.1.1. SEQUENCE-SPECIFIC PRIMER (SSP)-PCR
      • 7.2.1.2. SEQUENCE-SPECIFIC OLIGONUCLEOTIDE (SSO)-PCR
    • 7.2.2. SEQUENCING-BASED MOLECULAR ASSAYS
      • 7.2.2.1. SANGER SEQUENCING
      • 7.2.2.2. NEXT-GENERATION SEQUENCING (NGS)
  • 7.3. NON-MOLECULAR ASSAYS
    • 7.3.1. SEROLOGICAL ASSAYS
    • 7.3.2. MIXED LYMPHOCYTE CULTURE (MLC) ASSAYS

8. HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCTS & SERVICES

  • 8.1. INTRODUCTION
  • 8.2. REAGENTS AND CONSUMABLES
  • 8.3. INSTRUMENTS
  • 8.4. SOFTWARE AND SERVICES

9. HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. DIAGNOSTIC APPLICATIONS
  • 9.3. RESEARCH APPLICATIONS

10. HLA TYPING FOR TRANSPLANT MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. HOSPITALS AND TRANSPLANT CENTERS
  • 10.3. COMMERCIAL SERVICE PROVIDERS
  • 10.4. RESEARCH LABORATORIES AND ACADEMIC INSTITUTES

11. HLA TYPING FOR TRANSPLANT MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
    • 11.2.2. CANADA
  • 11.3. EUROPE
    • 11.3.1. GERMANY
    • 11.3.2. U.K.
    • 11.3.3. FRANCE
    • 11.3.4. REST OF EUROPE (ROE)
  • 11.4. ASIA-PACIFIC
    • 11.4.1. JAPAN
    • 11.4.2. CHINA
    • 11.4.3. INDIA
    • 11.4.4. REST OF ASIA-PACIFIC (ROAPAC)
  • 11.5. REST OF THE WORLD (ROW)

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SCENARIO
  • 12.4. RECENT DEVELOPMENTS
    • 12.4.1. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 12.4.2. NEW PRODUCT LAUNCHES, APPROVALS, AND PRODUCT ENHANCEMENTS
    • 12.4.3. STRATEGIC ACQUISITIONS
    • 12.4.4. GEOGRAPHIC EXPANSIONS

13. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 13.1. INTRODUCTION
  • 13.2. THERMO FISHER SCIENTIFIC, INC.
  • 13.3. IMMUCOR, INC.
  • 13.4. OLERUP SSP AB
  • 13.5. QIAGEN N.V.
  • 13.6. BIO-RAD LABORATORIES, INC.
  • 13.7. ILLUMINA, INC.
  • 13.8. AFFYMETRIX, INC.
  • 13.9. F. HOFFMANN-LA-ROCHE LIMITED
  • 13.10. LUMINEX CORPORATION
  • 13.11. ABBOTT LABORATORIES, INC.

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.5. AVAILABLE CUSTOMIZATIONS
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: TOTAL COST OF TRANSPLANT PROCEDURES IN THE U.S.: BY ORGAN TRANSPLANTATION STAGES (INCLUDING TRANSPLANT DIAGNOSIS AND MONITORING)
  • TABLE 2: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 3: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE FOR MOLECULAR ASSAYS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 4: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR MOLECULAR ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 5: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 6: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR SSP-PCR-BASED MOLECULAR ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR SSO-PCR-BASED MOLECULAR ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 10: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR SANGER SEQUENCING, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR NGS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR NON-MOLECULAR ASSAYS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 14: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR NON-MOLECULAR ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR SEROLOGICAL ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: HLA TYPING FOR TRANSPLANT MARKET SIZE FOR MLC ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 18: HLA-BASED TRANSPLANT DIAGNOSTIC REAGENTS AND CONSUMABLES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: HLA-BASED TRANSPLANT DIAGNOSTIC INSTRUMENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: HLA-BASED TRANSPLANT DIAGNOSTIC SOFTWARE AND SERVICES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 22: HLA-BASED TRANSPLANT DIAGNOSTICS MARKET SIZE FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: HLA-BASED TRANSPLANT DIAGNOSTICS MARKET SIZE FOR RESEARCH APPLICATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 25: HLA-BASED TRANSPLANT DIAGNOSTICS MARKET SIZE FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: HLA-BASED TRANSPLANT DIAGNOSTICS MARKET SIZE FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: HLA-BASED TRANSPLANT DIAGNOSTICS MARKET SIZE FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2014-2021
  • TABLE 30: U.S.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 31: U.S.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 32: U.S.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 33: U.S.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 34: CANADA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 35: CANADA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 36: CANADA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 37: CANADA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 38: EUROPE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 39: GERMANY: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 40: GERMANY: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 41: GERMANY: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 42: GERMANY: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021
  • TABLE 43: U.K.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 44: U.K.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 45: U.K.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 46: U.K.: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 47: FRANCE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 48: FRANCE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 49: FRANCE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 50: FRANCE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 51: ROE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 52: ROE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 53: ROE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 54: ROE: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 55: ASIA-PACIFIC: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 56: JAPAN: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 57: JAPAN: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 58: JAPAN: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 59: JAPAN: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 60: CHINA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 61: CHINA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 62: CHINA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 63: CHINA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 64: INDIA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 65: INDIA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 66: INDIA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 67: INDIA: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 68: ROAPAC: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 69: ROAPAC: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 70: ROAPAC: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 71: ROAPAC: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 72: ROW: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 73: ROW: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCTS & SERVICES, 2014-2021 (USD MILLION)
  • TABLE 74: ROW: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 75: ROW: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 76: TOP AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2012-2016
  • TABLE 77: TOP NEW PRODUCT LAUNCHES, APPROVALS, AND PRODUCT ENHANCEMENTS, 2012-2016
  • TABLE 78: TOP STRATEGIC ACQUISITIONS, 2012-2016
  • TABLE 79: TOP GEOGRAPHICAL EXPANSIONS, 2012-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES: 2000-2013
  • FIGURE 3: HEALTHCARE EXPENDITURE ACROSS MAJOR REGIONS: 2000-2013
  • FIGURE 4: HEALTHCARE SPENDING MATRIX: KEY MARKETS (2013)
  • FIGURE 5: INCREASE IN GERIATRIC POPULATION, BY COUNTRY (2011-2030)
  • FIGURE 6: INCREASE IN THE PROPORTION OF THE ELDERLY IN THE OVERALL POPULATION, BY COUNTRY (2011-2030)
  • FIGURE 7: PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION (1980-2010 VS. 2010-2040)
  • FIGURE 8: GLOBAL BURDEN OF CANCER, BY REGION (2005-2030)
  • FIGURE 9: NUMBER OF NEW CANCER CASES, BY COUNTRY (2012-2020)
  • FIGURE 10: INCREASING INCIDENCE OF VARIOUS CANCERS, 2008-2020
  • FIGURE 11: GLOBAL BURDEN OF CARDIOVASCULAR DISEASES, BY REGION (2005-2030)
  • FIGURE 12: NUMBER OF LIVING AND DECEASED ORGAN DONATIONS, BY COUNTRY (2010-2014)
  • FIGURE 13: NUMBER OF NEW PRODUCT LAUNCHES: HLA-BASED TRANSPLANT DIAGNOSTIC ASSAY VS. COMPETITIVE MODALITIES, 2012-2015
  • FIGURE 14: MOLECULAR ASSAY-BASED HLA TYPING TECHNOLOGY IS EXPECTED TO BE THE FASTEST-GROWING IMMUNOASSAY TECHNOLOGY BY 2021
  • FIGURE 15: BOTTOM-UP APPROACH: HLA-BASED TRANSPLANT DIAGNOSTICS INSTRUMENTS MARKET
  • FIGURE 16: BOTTOM-UP APPROACH: HLA-BASED TRANSPLANT DIAGNOSTIC REAGENTS AND CONSUMABLES MARKET
  • FIGURE 17: TOP-DOWN APPROACH
  • FIGURE 18: DATA TRIANGULATION
  • FIGURE 19: ASSUMPTIONS OF THE RESEARCH STUDY
  • FIGURE 20: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2016 VS. 2021
  • FIGURE 21: GEOGRAPHIC ANALYSIS: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCTS & SERVICES, 2016
  • FIGURE 22: GEOGRAPHIC ANALYSIS: HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2016 VS. 2021
  • FIGURE 23: GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2016 VS. 2021
  • FIGURE 24: HLA TYPING FOR TRANSPLANT MARKET SHARE, BY REGION, 2016
  • FIGURE 25: GROWING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE THE MARKET GROWTH FOR HLA-BASED TRANSPLANT DIAGNOSTICS
  • FIGURE 26: NORTH AMERICA IS EXPECTED TO DOMINATE THE HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, IN 2016
  • FIGURE 27: REAGENTS AND CONSUMABLES TO DOMINATE THE HLA-BASED TRANSPLANT DIAGNOSTICS PRODUCTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 28: NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF HLA TYPING FOR TRANSPLANT DIAGNOSTIC APPLICATIONS MARKET IN 2016
  • FIGURE 29: HOSPITALS AND TRANSPLANT CENTERS TO DOMINATE THE HLA TYPING FOR TRANSPLANT MARKET DURING THE FORECAST PERIOD
  • FIGURE 30: U.S. AND GERMANY ARE EXPECTED TO DOMINATE THE GLOBAL HLA-BASED TRANSPLANT DIAGNOSTICS MARKET TILL 2021
  • FIGURE 31: HLA TYPING FOR TRANSPLANT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 32: NUMBER OF ORGAN TRANSPLANT PROCEDURES, 2010-2013
  • FIGURE 33: PERCENTAGE CHANGE IN ANNUAL HEALTHCARE EXPENDITURE-DEVELOPED VS. DEVELOPING COUNTRIES (2010-2013)
  • FIGURE 34: VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED TO THE OVERALL PRODUCT PRICING DURING R&D PHASE
  • FIGURE 35: PORTER'S FIVE FORCES ANALYSIS: HLA TYPING FOR TRANSPLANT MARKET (2015)
  • FIGURE 36: GROWING ADOPTION OF PCR- AND NGS-BASED PRODUCTS IS PROPELLING REVENUE GROWTH FOR MOLECULAR ASSAYS MARKET
  • FIGURE 37: NGS-BASED DEVICES ARE EXPECTED TO FORM THE FASTEST-GROWING MOLECULAR ASSAY TECHNOLOGY SEGMENT TILL 2021
  • FIGURE 38: SEROLOGICAL ASSAY TECHNIQUE IS EXPECTED TO WITNESS POSITIVE MARKET GROWTH DURING 2016-2021
  • FIGURE 39: REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE THE HLA-BASED TRANSPLANT DIAGNOSTICS MARKET DURING 2016-2021
  • FIGURE 40: DIAGNOSTIC APPLICATIONS SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 41: THE HOSPITALS & TRANSPLANT CENTERS END-USER SEGMENT IS EXPECTED TO DOMINATE THE HLA TYPING FOR TRANSPLANT MARKET IN 2016
  • FIGURE 42: U.S. AND GERMANY TO GROW AT THE HIGHEST RATES IN THE HLA-BASED TRANSPLANT DIAGNOSTICS MARKET
  • FIGURE 43: NORTH AMERICAN HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT: 2016-2021
  • FIGURE 44: EUROPEAN HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT: 2016-2021
  • FIGURE 45: ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT: 2016-2021
  • FIGURE 46: ROW HLA-BASED TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT: 2016-2021
  • FIGURE 47: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS: KEY GROWTH STRATEGY ADOPTED BY A MAJORITY OF MARKET PLAYERS FROM 2012 TO 2016
  • FIGURE 48: GLOBAL HLA-BASED TRANSPLANT DIAGNOSTICS MARKET SHARE, KEY PLAYER, 2015
  • FIGURE 49: GROWING NUMBER OF AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS IS STIMULATING MARKET COMPETITION AMONG KEY PRODUCTS MANUFACTURERS
  • FIGURE 50: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS* (2015)
  • FIGURE 51: CAPACITY BUILDING AND CAPABILITY ENHANCEMENT: A KEY GROWTH STRATEGY ADOPTED BY MAJOR MARKET PLAYERS
  • FIGURE 52: THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • FIGURE 53: IMMUCOR, INC.: COMPANY SNAPSHOT
  • FIGURE 54: QIAGEN N.V.: COMPANY SNAPSHOT
  • FIGURE 55: BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 56: ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 57: AFFYMETRIX, INC.: COMPANY SNAPSHOT
  • FIGURE 58: F. HOFFMANN-LA-ROCHE LTD: COMPANY SNAPSHOT
  • FIGURE 59: LUMINEX CORPORATION: COMPANY SNAPSHOT
  • FIGURE 60: ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
Back to Top